Most importantly, TYMS, TK1, miR-26b-5p, and Sp1 panel should be further investigated as biomarkers of pathogenesis, prognosis, and differentiation of uLMS from other benign and malignant uterine tumors. This evidence concerns the gene SP1 and uterine cancer.